Johnson & Johnson vaccine, Ema: ok booster and third heterologous dose

A booster dose of Johnson & Johnson’s Covid vaccine may be considered, at least 2 months after the first, in people 18 years of age and older. It is one of the conclusions reached by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency Ema. The recommendation follows data showing how a booster of Janssen’s developed J&J vaccine, given at least 2 months after the first dose in adults, led to an increase in antibodies against Sars-CoV-2. “The risk of thrombosis in combination with thrombocytopenia (TTS) or other very rare side effects after a recall is not known and is carefully monitored”, adds the EU regulatory body in the note explaining the contents of the recommendation. As with all medicines, the EMA assures that it will continue “to examine all the data on the safety and efficacy of the Janssen vaccine”. J&J THIRD HETEROLOGICAL DOSE – Not only a homologous booster 2 months after the first J&J vaccine, but also a third heterologous dose to be administered after 2 of an mRna vaccine, another recommendation issued by the European Medicines Agency Ema. Its Committee for Medicinal Products for Human Use (CHMP) also concluded that “a booster dose with Johnson & Johnson’s Covid vaccine (developed by Janssen) can be administered after 2 doses of one of the authorized mRna vaccines. in the EU “, that is” Comirnaty * of Pfizer / BioNTech or Spikevax * of Moderna.